Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Instituto De Medicina Molecular has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being examined by 1 distinct examiner within 1 distinct art unit. The company's active patent prosecution is currently limited to this single technical interaction. This focus on 1 pending office action indicates a specific priority within the company's biotechnology research portfolio.
AGUIRRE, AMANDA L is the busiest examiner for the portfolio, with 1 pending office action. This examiner is responsible for the only pending action listed for the company. Prosecution success is currently dependent on the resolution of this matter by this specific examiner. Practitioners should focus on the examiner's past performance within the 1 assigned art unit to anticipate the likely trajectory of this pending action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AGUIRRE, AMANDA L | 1 | 77.3% | +15.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18299404 | SPIRO-LACTAM COMPOUNDS, PROCESS AND USES THEREOF | AGUIRRE, AMANDA L | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18299404 | SPIRO-LACTAM COMPOUNDS, PROCESS AND USES THEREOF | AGUIRRE, AMANDA L | 1626 | §102§112DP | Non-Final OA | — | Pending | Apr 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInstituto De Medicina Molecular has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Amanda L Aguirre has the most, with 1 of Instituto De Medicina Molecular's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
